Beyond statins: what to expect from add-on lipid regulating therapy?

Abstract excerpt

The winner takes it all The loser's standing small Beside the victory That's her destiny— Results of recent lipid lowering trials (Table 1) where new (dalcetrapib) and established agents (niacin) were tested on a background of statin therapy have been disappointingly negative. This outcome has been the cause of much consternation for those developing new lipid regulating drugs, and prompted reflection among...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Atherosclerosis and Cardiovascular Diseases
• Share to Cancer, Lipids, and Metabolism
• Share to Lipoproteins and Cardiovascular Health